SFA
ANIP icon

Sequoia Financial Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Sequoia Financial Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,423
Closed -$600K – 1293
2024
Q2 		$600K Buy
+9,423
New +$612K 0.01% 626

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sequoia Financial Advisors's ANIP Position: Q3 2024 in Review

Sequoia Financial Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2024, closing a stake of 9,423 shares — an estimated $600K sold.

Sequoia Financial Advisors first reported a position in ANIP in Q2 2024 and held it in 1 quarter. The position peaked at $600K in Q2 2024. 208 funds tracked by Wall St. Rank hold ANIP as of Q3 2024.

  • Sequoia Financial Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Sequoia Financial Advisors sold 9,423 ANI Pharmaceuticals shares in Q3 2024, an estimated $600K.
  • Sequoia Financial Advisors first reported a position in ANI Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Sequoia Financial Advisors's ANI Pharmaceuticals position peaked at $600K in Q2 2024.
  • 208 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2024.

Based on Sequoia Financial Advisors's 13F filing for Q3 2024, filed 21 Oct 2024.